THE INFLUENCE OF DOSAGE, AGE, AND COMEDICATION ON STEADY-STATE PLASMALAMOTRIGINE CONCENTRATIONS IN EPILEPTIC CHILDREN - A PROSPECTIVE-STUDY WITH PRELIMINARY ASSESSMENT OF CORRELATIONS WITH CLINICAL-RESPONSE
A. Bartoli et al., THE INFLUENCE OF DOSAGE, AGE, AND COMEDICATION ON STEADY-STATE PLASMALAMOTRIGINE CONCENTRATIONS IN EPILEPTIC CHILDREN - A PROSPECTIVE-STUDY WITH PRELIMINARY ASSESSMENT OF CORRELATIONS WITH CLINICAL-RESPONSE, Therapeutic drug monitoring, 19(3), 1997, pp. 252-260
The effects of age, dosage, and type of comedication on plasma lamotri
gine (LTG) concentrations and the relationship between plasma drug lev
els and clinical response were evaluated in a prospective study of 45
patients, aged 3 to 38 years, with epilepsy uncontrolled by convention
al anticonvulsant therapy. Six of the 45 patients were on single-drug
therapy, and 39 were on two to five concurrently administered antiepil
eptic drugs when LTG was added, Thirteen patients were assessed at thr
ee or more LTC dosage levels. Within individuals, steady state plasma
LTG concentrations increased linearly with increasing daily dosage ove
r the examined dose range (25 to 575 mg/day or 0.75 to 21 mg/kg . day)
. Among patients also receiving enzyme-inducing agents, such as carbam
azepine, barbiturates, or phenytoin, plasma LTG concentrations normali
zed to a 1 mg/kg daily dose were lower In children aged 3 to 6 years (
0.30 +/- 0.17 mu g/ml; n = 6) than in the older children (0.43 +/- 0.1
8 mu g/ml; n = 12) and adolescents/adults (0.68 +/- 0.26 mu g/ml; n =
10). In patients treated with valproate, the age dependency of plasma
LTG was less evident, possibly because of a smaller sample size and th
e confounding effect of comedication, Within any given age group, dose
-normalized LTG concentrations were about five-fold higher in patients
comedicated with valproic acid than in those comedicated with enzyme
inducers, Twenty patients showed a favorable response (with a greater
than or equal to 40% reduction in seizure frequency compared with the
pre-LTG period) and continued on long-term treatment, Plasma drug conc
entrations in these apparent responders were highly variable and did n
ot differ significantly from those observed in nonresponders (6.6 +/-
5.2 versus 4.8 +/- 3.3 mu g/ml). These findings show that plasma LTG c
oncentrations exhibit a wide interindividual variability under the inf
luence of age and type of comedication, but they are predictably relat
ed to dosage within individual patients, Although there was no apparen
t relationship between drug levels and clinical response in this diffi
cult-to-treat population, further studies on the potential value of mo
nitoring plasma LTG concentrations are indicated.